Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(0.86)
# 3,820
Out of 4,944 analysts
317
Total ratings
24.36%
Success rate
-25.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FEMY Femasys | Maintains: Buy | $12 → $8 | $0.73 | +995.89% | 25 | Aug 11, 2025 | |
| CNTX Context Therapeutics | Maintains: Buy | $5 → $4 | $0.68 | +488.24% | 12 | Aug 7, 2025 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $10 → $9 | $2.16 | +316.67% | 2 | Jul 22, 2025 | |
| INKT MiNK Therapeutics | Downgrades: Neutral | $35 | $14.20 | +146.48% | 13 | Jul 15, 2025 | |
| RAPT RAPT Therapeutics | Maintains: Buy | $6 → $27 | $10.90 | +147.71% | 2 | Jul 10, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $40 → $20 | $2.85 | +601.75% | 10 | Jul 7, 2025 | |
| NXTC NextCure | Reiterates: Buy | $36 | $4.84 | +644.57% | 9 | Jul 1, 2025 | |
| ACLX Arcellx | Reiterates: Buy | $115 | $72.50 | +58.62% | 13 | Jun 16, 2025 | |
| ARTV Artiva Biotherapeutics | Assumes: Buy | $12 | $2.47 | +385.83% | 1 | Jun 11, 2025 | |
| AGEN Agenus | Upgrades: Buy | $25 | $4.81 | +419.75% | 18 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $38 | $20.09 | +89.15% | 10 | Jun 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $5.31 | +464.97% | 20 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $3.11 | +253.70% | 11 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $0.72 | +4,341.98% | 14 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $11.51 | +2,333.72% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $14.49 | +148.45% | 1 | Apr 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.27 | +252.42% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.31 | +816.03% | 13 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $3.19 | +840.44% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $1.25 | +1,420.00% | 12 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $1.96 | +818.37% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $210 | $6.84 | +2,970.18% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $0.77 | +805.80% | 14 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.35 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $24 | $9.67 | +148.19% | 5 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $58 | $35.38 | +63.93% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $0.76 | +2,277.81% | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $2.63 | - | 15 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $11.34 | +235.10% | 18 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $2.25 | +1,366.67% | 14 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $4.45 | - | 1 | Apr 25, 2024 |
Femasys
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $0.73
Upside: +995.89%
Context Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $0.68
Upside: +488.24%
SAB Biotherapeutics
Jul 22, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $2.16
Upside: +316.67%
MiNK Therapeutics
Jul 15, 2025
Downgrades: Neutral
Price Target: $35
Current: $14.20
Upside: +146.48%
RAPT Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $6 → $27
Current: $10.90
Upside: +147.71%
Jasper Therapeutics
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $2.85
Upside: +601.75%
NextCure
Jul 1, 2025
Reiterates: Buy
Price Target: $36
Current: $4.84
Upside: +644.57%
Arcellx
Jun 16, 2025
Reiterates: Buy
Price Target: $115
Current: $72.50
Upside: +58.62%
Artiva Biotherapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $12
Current: $2.47
Upside: +385.83%
Agenus
Jun 4, 2025
Upgrades: Buy
Price Target: $25
Current: $4.81
Upside: +419.75%
Jun 4, 2025
Upgrades: Buy
Price Target: $22 → $38
Current: $20.09
Upside: +89.15%
Apr 28, 2025
Reiterates: Buy
Price Target: $30
Current: $5.31
Upside: +464.97%
Apr 24, 2025
Reiterates: Buy
Price Target: $11
Current: $3.11
Upside: +253.70%
Apr 22, 2025
Reiterates: Buy
Price Target: $32
Current: $0.72
Upside: +4,341.98%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $11.51
Upside: +2,333.72%
Apr 9, 2025
Initiates: Buy
Price Target: $36
Current: $14.49
Upside: +148.45%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $2.27
Upside: +252.42%
Apr 1, 2025
Reiterates: Buy
Price Target: $12
Current: $1.31
Upside: +816.03%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $3.19
Upside: +840.44%
Mar 28, 2025
Reiterates: Buy
Price Target: $19
Current: $1.25
Upside: +1,420.00%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $1.96
Upside: +818.37%
Mar 26, 2025
Reiterates: Buy
Price Target: $210
Current: $6.84
Upside: +2,970.18%
Mar 26, 2025
Reiterates: Buy
Price Target: $7
Current: $0.77
Upside: +805.80%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.35
Upside: -
Feb 26, 2025
Upgrades: Buy
Price Target: $24
Current: $9.67
Upside: +148.19%
Feb 24, 2025
Reiterates: Buy
Price Target: $58
Current: $35.38
Upside: +63.93%
Feb 3, 2025
Reiterates: Buy
Price Target: $18
Current: $0.76
Upside: +2,277.81%
Jan 14, 2025
Reiterates: Neutral
Price Target: n/a
Current: $2.63
Upside: -
Jan 14, 2025
Reiterates: Buy
Price Target: $38
Current: $11.34
Upside: +235.10%
Nov 15, 2024
Reiterates: Buy
Price Target: $33
Current: $2.25
Upside: +1,366.67%
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $4.45
Upside: -